|Day Low/High||0.66 / 0.71|
|52 Wk Low/High||0.61 / 7.80|
Milestone Execution Positions the Company for Expedited Progress in 2019
Results and Validation of ApoGraft technology from a variety of sources could lead to a more cost-effective solution for the cell therapy industry.
The Collaboration will be led by Renowned Cell and Gene Therapy Experts Dr. John DiPersio and Dr. Mark Schroeder with Advisory support to Cellect by Prof. Negrin of Stanford and Dr. Cutler of Harvard Medical School
Supports Collaborations with Cell and Gene Therapy Companies
Recent FDA Hiring Decision Highlights Growing Importance of Cell and Gene Therapy Companies
The Korea-Israel Industrial R&D Foundation (KORIL-RDF) approves grant for the collaboration between Cellect and Cell2in, providing financing for the joint project
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
Company's Securities to Continue Trading Only on NASDAQ Stock Exchange in US
Method of treatment patent provides important protection in type I diabetes, inflammatory bowel disease, graft versus host disease and transplant rejection
Companies will test lowering transplant rejection symptoms using Cellect's ApoGraft method for stem cells selection
Raised Gross Proceeds of $8.4 Million through Pricing of July U.S. Initial Public Offering
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.